It is noteworthy that Janssen [74] observed ERK pathway activity as an important factor in the synergistic effect of the combination of Venetoclax and Gilteritinib in patients with FLT3 wild-type high-risk AML, and how these drugs work together to suppress the MCL-1 protein. The gene discussed is FLT3; the disease is acute myeloid leukemia.